International Eurasian Academy of Sciences, IEAS

Academician

Luo ZHANG

Profile:

Elected Academician of the International Eurasian Academy of Sciences in 2020, Professor Luo Zhang is a Chinese physician and researcher in rhinology and allergology whose professional work has focused on the pathogenesis, diagnosis, treatment, and prevention of chronic nasal diseases, particularly allergic rhinitis and chronic rhinosinusitis. Born in 1969, he received his bachelor’s degree in clinical medicine from Capital Medical University in 1993 and his doctorate in medicine in 2000, followed by a doctorate in management from Tianjin University and postdoctoral research at the University of Massachusetts Medical School from 2001 to 2003. He has spent his academic career at Beijing Tongren Hospital, Capital Medical University, where he became President and Deputy Party Secretary in 2020. He also serves as Director of the Beijing Institute of Otolaryngology, the Beijing Key Laboratory of Rhinology, the Beijing Laboratory of Allergic Diseases, and the National Engineering Research Centre for Innovative Drugs for Allergic Diseases. A Cheung Kong Scholar Distinguished Professor and recipient of the National Science Fund for Distinguished Young Scholars, he has held leadership positions in the Asia Pacific Association of Allergy, Asthma and Clinical Immunology, the Chinese Society of Allergy, the Otolaryngologists Branch of the Chinese Medical Doctor Association, and the International Society of Inflammation and Allergy of the Nose. He has also served on the Executive Council of the World Allergy Organization and as Editor-in-Chief of Asia Pacific Allergy. His honours include two Second Prizes of the National Science and Technology Progress Awards and the title of National Outstanding Scientific and Technological Worker.

Back to list page →

Professor Zhang’s research has centred on the epidemiology, pathogenesis, prevention, and treatment of allergic rhinitis and chronic rhinosinusitis. In 2005, he initiated a nationwide epidemiological survey of allergic rhinitis in China and subsequently established a national pollen-monitoring network, providing data that have supported the inclusion of pollen forecasts in meteorological services. His work on regional allergen panels has also contributed to more targeted and accessible allergen testing. He has investigated the effects of air pollutants on pollen allergenicity and developed diagnostic approaches based on eosinophils in nasal secretions to improve the differentiation of rhinitis subtypes. In chronic rhinosinusitis, his research has addressed endotype-based approaches to the diagnosis and treatment of nasal polyps. His team conducted a randomised controlled trial of the IL-4 receptor alpha monoclonal antibody stapokibart for moderate-to-severe seasonal allergic rhinitis, with results published in Nature Medicine in 2025. He has led more than 20 national research projects and contributed to multiple national and municipal science and technology awards. As first or corresponding author, he has published more than 560 papers, including over 260 in English, and has co-authored or edited 11 monographs. He has contributed to Chinese and international clinical guidelines on allergic rhinitis, allergen immunotherapy, and chronic rhinosinusitis, edited an English-language Springer monograph on chronic rhinosinusitis, and participated in the development of more than 20 international guidelines. Through sustained clinical and translational research, guideline development, and international collaboration, Professor Zhang has contributed to the development of rhinology and allergology in China and to its engagement with international research and clinical practice.